Pertuzumab biosimilar (JHL Biotech)

帕妥珠单抗生物类似药（JHL Biotech）

Report date: 2022/07/01 10:24:33

Base Information

Drug NamePertuzumab biosimilar (JHL Biotech)

Drug Alias NameAnti-2C4 monoclonal antibody培妥珠单抗Pertuzumabum珀妥珠单抗帕妥株单抗 +[7]

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Biosimilar

Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 antagonists

TargetsReceptor protein-tyrosine kinase erbB-2

Therapy Area/IndicationsBreast Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryTaiwan

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesEden Biologics Inc

China Registration ClassN/A

Inactive CompaniesN/A

Active IndicationsBreast Neoplasms

Inactive IndicationsN/A

ATC CodeN/A